Kollewe, Katja
Gaul, Charly
Gendolla, Astrid
Sommer, Katherine
Funding for this research was provided by:
Medizinische Hochschule Hannover (MHH)
Article History
Received: 14 April 2021
Accepted: 14 May 2021
First Online: 2 June 2021
Declarations
:
: Before study initiation, all investigators obtained ethical approval from their respective ethics committees. The study was conducted in accordance with the International Council on Harmonisation Guideline for Good Clinical Practice. Informed consent was obtained from each patient before enrolment.
: Not applicable.
: Financial arrangements of the authors with companies whose products may be related to the present report are listed below, as declared by the authors.<b>Katja Kollewe, MD</b>, has received travel grants and honoraria for lectures or advisory boards from Allergan, an AbbVie Company, Biogen, Ipsen, Lilly, Merz, Novartis, and Teva. KK does not hold stocks of any pharmaceutical or medical device companies. <b>Charly Gaul, MD</b>, has received honoraria for consulting and lectures within the past three years from Allergan, an AbbVie Company, Lilly, Novartis Pharma, Hormosan Pharma, Grünenthal, Sanofi-Aventis, Weber & Weber, Lundbeck and TEVA. He does not hold any stocks of pharmaceutical companies. He is honorary secretary of the German Migraine and Headache Society. <b>Astrid Gendolla, MD</b>, has received fees for lectures and consulting in the last 3 years from Allergan, an AbbVie Company, Reckitt Benckiser, St. Jude Medical, Bayer, Grünenthal, Mundipharma, Zahnärztekammer KVNO, GAF, Novartis, Lilly, Perfood, and Teva. She does not hold stocks of any pharmaceutical companies. She is vice president of the German Pain Society. <b>Katherine Sommer, PhD</b>, is an employee of AbbVie Inc. and receives stock or stock options.